Conference Coverage

Triage MS-related ED visits to reduce unnecessary treatment


 

AT ACTRIMS FORUM 2016

References

NEW ORLEANS – The majority of multiple sclerosis–related emergency department visits in a recent chart review were related to pseudoflares or MS-related complications, rather than to true MS relapse.

The findings suggest that many diagnostic tests, treatments, and hospital admissions are unnecessary, Dr. Hesham Abboud of the Cleveland Clinic and his colleagues reported in a poster at the meeting held by the Americas Committee for Treatment and Research in Multiple Sclerosis.

©EyeMark/thinkstockphotos.com

Of 97 MS-related visits among 75 patients, 33 were for new neurologic symptoms, 29 were for worsening of preexisting symptoms, and 36 were for MS-related complications. New relapse was diagnosed in only 27 visits (27.8%), and urinary tract infections were found in about one-third of patients presenting with either urinary or neurologic symptoms, the investigators said.

New MRIs were ordered in 37 patients (38.1%); 89 emergency department visits (91.7%) resulted in hospital admissions and 40.4% were related to neurology; and steroid treatment was used in 24 visits (24.7%), 7 of which were for worsening of preexisting symptoms, the investigators said.

Of the visits involving new neurologic symptoms, one-third were not from relapse; 59% of the MRIs done in those situations were positive for enhancing or new lesions. Of the visits with worsening preexisting symptoms, only 16.6% were associated with a new relapse, and 28.5% of MRIs done in those situations were positive, the investigators said.

Although many ED visits among MS patients are driven by neurologic complaints, true relapse is rarely present, and not all those with true relapse require hospital admission and steroid treatment, they noted, concluding that developing a care path and triaging system for MS patients in the ED could prevent unnecessary MRIs, steroid treatment, and hospital admissions.

The investigators reported having no disclosures.

sworcester@frontlinemedcom.com

Recommended Reading

Brian Sandroff, PhD
ICYMI Multiple Sclerosis
VIDEO: Progressive MS trial failures provide lessons for future success
ICYMI Multiple Sclerosis
Potential biomarkers of gray matter damage in MS identified
ICYMI Multiple Sclerosis
Treatment justified even for moderately advanced MS disability
ICYMI Multiple Sclerosis
Blood-borne biomarkers of MS relapse identified
ICYMI Multiple Sclerosis
Ocrelizumab subanalysis hints at better efficacy with active inflammatory lesions
ICYMI Multiple Sclerosis
VIDEO: MS stem cell therapy research progresses, including oligodendrocyte progenitor trial
ICYMI Multiple Sclerosis
Positive headway reported for progressive multiple sclerosis
ICYMI Multiple Sclerosis
VIDEO: Novel tools measure disease progression in MS
ICYMI Multiple Sclerosis
Fingolimod improved gait impairment in small study
ICYMI Multiple Sclerosis